Official Title Dance-Based Avenues to Advance Nonpharmacologic Treatment of Chemotherapy Effects (DAANCE): A Multi-Center Trial

Purpose

This study will teach tango dance to try to help with neuropathy symptoms. Tango dancing classes will take place for 2 times a week for 8 weeks. You will be asked about symptoms such as numbness, tingling, fatigue, pain, and balance. There is a 6 month follow up period where we will ask you to tell us about your symptoms via an app. 

Could this study be right for you?

1. Breast cancer survivors stage I-IV

2. Exposure to chemotherapy with the last exposure being at least 3 months prior to study participation

3. Must be ambulatory

 

Age Range

40 years and up

Official Title A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis suppurativa

Purpose

This study is being done to see how well remibrutinib works for people who have hidradenitis suppurativa

 

Could this study be right for you?

- Subject must have a diagnosis of moderate to severe hidradenitis suppurativa (HS) for at least 6 months with lesions in 2 distinct areas

- Subject must be in good general health with no history of tuberculosis, HIV, or hepatitis B or C

- Subject must have no recent history (within 6 months) of significant medical conditions such as a heart attack or stroke

- Subject must not be taking anticoagulant medication (ex. warfarin) or dual anti-platelet therapy (ex. acetylsalicylic acid + clopidogrel)

Age Range

18 years and up

Official Title Creating a Mobile Health Program for Teens with Congenital Heart Disease

Purpose

The purpose of this study is to learn more about what teens with congenital heart disease want in a program that helps them learn more about living with congenital heart disease, dealing with stress, and staying away from e-cigarettes. The information from your participation may help us understand how we can improve the program and make it more interesting and appealing for teens.

Could this study be right for you?

• Have a diagnosis of a structural congenital heart defect
• No cognitive impairments limiting ability to complete study interview/questionnaires
• Proficient in English
• Have access to a device that can connect to the internet
• Not leaving the country at any point during study participation

**This study is invite only. Study staff will contact you if you are invited to participate.**

Age Range

12 - 18 years

Official Title A User-Friendly, Non-Invasive Neuro-Orthosis That Restores Volitionally Controlled Grasp Functions for SCI Survivors with Tetraplegia

Purpose

This study is testing a new wearable device designed to help people with spinal cord injuries regain movement and control in their hands. The device uses electrical signals from the muscles to assist with hand movements. We are exploring whether using this device can improve hand function, support long-term recovery, and help track progress over time. The results will guide future development and testing to bring this technology into everyday rehabilitation and home use.

This is a 20 week study where you will complete a 12-week rehabilitation training protocol (3x/week, 1-2 hours/session) with our study therapist.  Additionally, you will participate in six sessions where clinical assessments will be conducted to measure your arm/hand function.

 

Could this study be right for you?

• Cervical spinal cord injury sustained at least 1 year ago 
• Unable to grasp and manipulate objects to allow independent performance of activities of daily living
• Able to actively move your shoulder and elbow 
• Not currently active in upper extremity rehabilitation

Age Range

22 years and up

Official Title Perceptions of Vaping Products Among Young Adults

Purpose

This study will examine how young adults perceive new vaping products.

Participation involves taking part in a study at The Center for Tobacco Research. You will be asked to attend 3 study visits over the course of 3 weeks (1 visit/week for 3 weeks). You will be asked to bring your own preferred e-cigarette device to each study visit.

 

Could this study be right for you?

• Must be a current e-cigarette user
• Must be willing to attend 3 in-person study visits

Age Range

21 - 34 years

Official Title The ICE Study: Perceptions of E-Cigarettes and Synthetic Cooling Agents

Purpose

This study will examine the influence of synthetic cooling agents in e-cigarettes on vaping behavior and aims to find out how adding artificial cooling ingredients affects how people use a product and their exposure to harmful chemicals.

Your participation in this study will last for 4 sessions, 1 session per week for 4 weeks.

 

 

Could this study be right for you?

• Must be a current e-cigarette user
• Must be willing to attend four in-person study sessions

Age Range

21 - 29 years

Official Title Visual Search Strategy in Neurodivergent Populations

Purpose

The NeuroLab is looking at differences in how Autistic and Neurotypical adults pay attention to their surrounding environment. Previous studies have found that autistic individuals are often better at focusing on visual cues—things they see in their environment—and this study wants to understand what causes that difference. To do so, participants will come in for 2-3 hours and complete computer games, paper and pencil games, and surveys. The goal is to learn how attention works for different people and why Autistic individuals might focus on visual cues differently.

Could this study be right for you?

- Have a medical diagnosis of Autism

- Have normal or corrected color vision

- Can communicate verbally

Age Range

18 - 40 years

Official Title AN OBSERVATIONAL, LONG-TERM SAFETY STUDY OF TZIELD® (TEPLIZUMAB-MZWV) IN PATIENTS WITH STAGE 2 TYPE 1 DIABETES

Purpose

The objective of the study is to test the safety and efficacy of TZIELD over the course of 10 years in patients with Stage 2, Type 1 Diabetes, as well as the prevention of Stage 3, Type 1 Diabetes. 

Could this study be right for you?

Inclusion Criteria:

TZIELD-Exposed Cohort
1. Patients in the US diagnosed with Stage 2 T1D who are planned to initiate TZIELD treatment according to the currently approved label or who have initiated TZIELD treatment within 6 months prior to enrollment:
− Day 1: 65 μg/m²
− Day 2: 125 μg/m²
− Day 3: 250 μg/m²
− Day 4: 500 μg/m²
− Days 5 through 14: 1,030 μg/m² per day
− Cumulative dose is approximately 11,240 μg/m²

2. Appropriate written informed consent/assent as applicable for the age of the patient

TZIELD-Unexposed Cohort
1. Patients in the US diagnosed with Stage 2 T1D but who are not treated with TZIELD
2. Appropriate written informed consent/assent as applicable for the age of the patient

Exclusion Criteria:
1. Patients who initiated TZIELD treatment more than 6 months prior to enrollment
2. Patients who had participated in a previous clinical trial for TZIELD
3. Patients in an ongoing clinical trial of an investigational product or who had ended participation within 6 months prior to study enrollment; patients participating in other observational studies may be enrolled.

Age Range

18 - 70 years

Official Title A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism

Purpose

The purpose of this study is to evaluate if Armour Thyroid is safe and effective in the treatment of hypothyroidism.

 

You will participate in this study for up to 90 weeks. The study will be conducted in 3 treatment periods plus a Screening and Follow-up period: • Screening period (up to 28 days)– the dose of Armour Thyroid will be adjusted as needed to ensure your Hypothyroidism is well controlled  • Follow-up period (approximately 35 days following the last dose of study drug)  

Could this study be right for you?

• Were diagnosed with hypothyroidism at least 12 months ago

• Have been on a stable dose of T4 (like levothyroxine or Synthroid) for at least 3 months

• Have a recent TSH level between 0.45–4.12 mIU/L

• Are between BMI 18 and 40

• Are not pregnant or breastfeeding and use birth control if needed

• Are not allergic to thyroid meds or pork products

• Have no recent drug/alcohol abuse or severe liver/kidney disease

• Are not in another clinical trial

• Take no more than 200 mcg of T4 daily

Age Range

18 - 75 years

Official Title Biomechanical Metrics of Movement Relative to Total Knee Arthroplasty

Purpose

This study aims to understand how a total knee replacement surgery (TKR) affects muscle function and movement in the lower body. It focuses on four key areas:

1. Examining how TKR changes the way muscles work in the lower body.

2. Exploring how these muscle changes relate to the forces people experience when walking and doing daily activities after surgery.

3. Connecting muscle function to how well patients feel and move after TKR.

4. Identifying different types of TKR patients based on their physical traits, movement patterns, and medical history to see how they compare.

Could this study be right for you?

• Must be scheduled to receive a total knee replacement within the next 2 months
• Have a body mass index (BMI) < 40
• Do not require the use of a cane or other assistive device when walking, climbing stairs, and getting up from a chair

Exclusion criteria varies; please contact Study Coordinator for more information

Age Range

18 years and up

Official Title Effects of Acute and Chronic Ketone Ester Consumption on Exercise Tolerance and Cardiac Function in Subjects with Diabetes

Purpose

This placebo-controlled study is being done to evaluate the effects of a ketone ester drink on exercise performance and heart health in a group of subjects diagnosed with type 2 diabetes.

Could this study be right for you?

There are additional exclusion criteria, study staff will screen fully before enrollment.

Age Range

18 - 80 years

Official Title Radiotracer Imaging of Lower Extremity Skeletal Muscle Perfusion in Patients with Peripheral Arterial Disease

Purpose

The purpose of this study is to look at a new method to evaluate blood flow to the calves and feet. 

Peripheral Artery Disease (PAD) patient outcomes will be evaluated for up to 12 months after their revascularization procedure to assess how early changes in SPECT-derived foot perfusion relate to rates of diabetic wound healing and limb salvage. Outcomes will be specifically evaluated at 3, 6, 9, and 12 months after revascularization at the time of their follow-up clinic visits to the OSU Comprehensive Wound Center at OSU Hospital East. Primary outcomes of interest will be 1) changes in wound size and healing, 2) minor or major amputations of the lower extremity, and 3) any subsequent interventional procedures, such as balloon angioplasty, stenting, or surgical bypass.

 

Could this study be right for you?

Heathly Volunteers with out previous cardiovascular disease

Or 

PAD

Age Range

18 years and up